PLN-101095
Advanced Solid Tumors
Key Facts
About Pliant Therapeutics
Pliant Therapeutics is pioneering a new approach to treating fibrotic diseases by targeting the biological pathways that drive fibrosis, specifically through integrin-mediated activation of TGF-β. The company's most advanced program, bexotegrast, has demonstrated promising safety and efficacy signals in mid-stage clinical trials for IPF and PSC, positioning it as a potential first-in-class oral therapy. With a robust pipeline of integrin-targeted candidates and a strong intellectual property position, Pliant aims to address the substantial market opportunity in fibrotic diseases, which currently lack effective anti-fibrotic treatments.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| SHR-1701 | Jiangsu Hengrui Medicine | Phase 1 |
| BAY 1895344 | Bayer | Phase 1 |
| HS-10342 | Hansoh Pharma | Phase 1/2 |
| ANKTIVA® + M-ceNK | ImmunityBio | Phase 1 |
| DFTX-101 | Definium Therapeutics | Phase 1/2 |
| REC-617 | Recursion Pharmaceuticals | Phase 1/2 |
| ZW220 | Zymeworks | Preclinical |
| NX-1607 | Nurix Therapeutics | Phase 1a |
| IMA402 (TCR Bispecific) | Immatics | Phase 1 |
| IMA403 (TCR Bispecific) | Immatics | Pre-clinical |
| BCA101 | Bicara Therapeutics | Phase 1 |
| AN4005 | Adlai Nortye | Preclinical |